CADTH Canadian Drug Expert Committee recommendation: Tenofovir alafenamide (Vemlidy -- Gilead Sciences Canada, Inc.) indication : chronic hepatitis B.
The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: the drug plan cost of TAF should not exceed that of the lowest-cost preparat...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2018, March 28, 2018
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: the drug plan cost of TAF should not exceed that of the lowest-cost preparation of tenofovir disoproxil fumarate (TDF) |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (6 pages) |